头颈部鳞状细胞癌抗血管生成治疗的研究进展  

Advances in antiangiogenic therapy in head and neck squamous cell carcinoma

作　　者：李智[1] 吕建建 李军[1] Li Zhi;Lyu Jianjian;Li Jun(Department of Dermatology,Qingdao City Hospital,Qingdao,Shandong,266071,China)

机构地区：[1]青岛市市立医院皮肤科,山东青岛266071

出　　处：《当代医学》2020年第26期192-194,共3页Contemporary Medicine

摘　　要：头颈部鳞状细胞癌(squamous cell carcinoma of the head and neck,SCCHN)在临床中发病率较高,严重影响患者身心健康,而肿瘤的增殖、转移与新血管生成密切相关。多种因子在新血管生成中发挥重要作用,其中血管内皮生长因子(vascular endothelial growth factor,VEGF)主要发挥促血管生成作用,而血管内皮抑制素则发挥抵制作用。抗血管生成方案广泛应用于临床中,如VEGF单克隆抗体、血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)酪氨酸激酶抑制剂、血管内皮抑素等。本文对SCCHN抗血管生成治疗进展进行简要综述,旨在为临床治疗提供指导。Head and neck squamous cell carcinoma(SCCHN) is more frequent in clinic, which has serious effect on the physical and mental health of patients, and the proliferation and metastasis of tumor are closely related to new angiogenesis. Many factors play an important role in neovascularization, among which vascular endothelial growth factor(VEGF) promoting angiogenesis, while vascular endothelial inhibitory effect. Antiangiogenic schemes are widely used in clinic, such as VEGF monoclonal antibody, vascular endothelial growth factor receptor(VEGFR) tyrosine kinase inhibitor, vascular endostatin and so on. This article reviews the progress of anti-angiogenesis therapy for SCCHN to provide guidance for clinical treatment.

关 键 词：头颈部鳞状细胞癌 抗血管生成治疗 研究进展 

分 类 号：R739.91[医药卫生—肿瘤]